cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Acorda Therapeutics Inc
41 own
38 watching
Current Price
$0
$-0.04
(-4.37%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
23.85M
52-Week High
52-Week High
2.29
52-Week Low
52-Week Low
0.2611
Average Volume
Average Volume
0.08M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
3.3095
iconMarket Capitalization23.85M
icon52-Week High2.29
icon52-Week Low0.2611
iconAverage Volume0.08M
iconDividend Yield--
iconP/E Ratio3.3095
What does the Acorda Therapeutics Inc do?
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in Parkinson's disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in Parkinson's disease; SYN120, which is in Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Read More
How much money does Acorda Therapeutics Inc make?
News & Events about Acorda Therapeutics Inc.
Business Wire
1month ago
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has revised and updated the long-term financial guidance most recently included in its November 1, 2022 press release announcing its financial results for the third quarter of 2022. The revised guidance corrects certain errors...
Business Wire
2 months ago
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Companys stockholders approved the Reverse Stock Split proposal at its reconvened Special Meeting of Stockholders. We are grateful to our shareholders who supported this proposal at a ratio of almost two and a half to one...
Business Wire
3 months ago
Acorda Therapeutics, Inc. (Nasdaq: ACOR) convened its Special Meeting of Stockholders on November 4, 2022, and a proposal to adjourn the meeting was approved in order to provide stockholders with additional time to vote on Proposal Two, Reverse Stock Split. The Special Meeting will be reconvened on...
Business Wire
3 months ago
Acorda Therapeutics, Inc. (Nasdaq: ACOR) will hold a virtual, video Q&A with its CEO, Ron Cohen, M.D., on Friday, October 28 at 1:00pm ET, 10:00am PT. The call will review the items on the ballot for Acordas Special Meeting of Shareholders on November 4, 2022. Participants will be able to...
PR Newswire
3 months ago
Thinking about buying stock in Federated National, Acorda Therapeutics, Nio, Avenue Therapeutics, or Visa? Thinking about buying stock in Federated National, Acorda Therapeutics, Nio, Avenue Therapeutics, or Visa? PR Newswire NEW YORK, Oct. 17, 2022 NEW YORK, Oct. 17, 2022 /PRNewswire...
Frequently Asked Questions
Frequently Asked Questions
What is Acorda Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Acorda Therapeutics Inc shares?
plus_minus_icon
How can I buy Acorda Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Acorda Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Acorda Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Acorda Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Acorda Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Acorda Therapeutics Inc?
plus_minus_icon
What percentage is Acorda Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Acorda Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.04
(-4.37%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Rubius Therapeutics Inc
Rubius Therapeutics Inc
$0.25
$-0.02 (-6.20 %)
Accelerate Diagnostics Inc
Accelerate Diagnostics Inc
$0.66
$-0.01 (-1.65 %)
Cellectis S.A.
Cellectis S.A.
$2.33
$-0.05 (-2.04 %)
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$471.80
$0.00 (0.00 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Rubius Therapeutics Inc
Rubius Therapeutics Inc
$0.25
$-0.02 (-6.20 %)
Accelerate Diagnostics Inc
Accelerate Diagnostics Inc
$0.66
$-0.01 (-1.65 %)
Cellectis S.A.
Cellectis S.A.
$2.33
$-0.05 (-2.04 %)
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
$471.80
$0.00 (0.00 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00